As you probably have heard by now, the landscape of federal drug policy experienced its most seismic disruption in our lifetime when the United States Department of Justice and the Drug Enforcement Administration (DEA) issued a final order reclassifying medical cannabis from Schedule I to Schedule III of the Controlled Substances Act in late April.
The directive affected Food and Drug Administration (FDA)-approved cannabis medications and state-licensed medical marijuana products, leaving adult-use recreational cannabis in regulatory limbo for the time being. We’ll explain what that all means and how Ohioans can participate in the process:
Shift in Federal Oversight for Medical Cannabis Only
For cannabis business operators, the most immediate and profound impact is economic. Moving medical cannabis to Schedule III provides immediate relief from Internal Revenue Code Section 280E, a long-loathed tax provision that historically barred cannabis businesses from deducting standard operating expenses like rent, payroll, and marketing. Medical dispensary owners can now claim these deductions, a financial windfall that industry experts predict will inject billions of dollars back into the legal market.
However, federal oversight has not disappeared; it has simply changed its form. Corporate legal firms have pointed out that state-licensed medical operators are now scrambling to integrate into the federal regulatory framework governing Schedule III substances. This requires expedited DEA registration, strict recordkeeping, specific labeling protocols, and enhanced security compliance.
Meanwhile, the broader market remains fragmented because recreational, adult-use cannabis was explicitly excluded from this immediate shift and remains a Schedule I substance, creating a bifurcated legal reality that will be debated further during upcoming administrative hearings.
Employment attorneys are also preparing for a wave of litigation regarding workplace rules. As noted by the workplace law firm Littler, reclassifying medical marijuana as a drug with an accepted medical use gives the estimated six million medical cardholders nationwide significantly more leverage. Employees can now present their valid state medical certifications to explain positive workplace drug screenings. This shift forces human resources departments to reevaluate drug-free workplace policies and seriously consider medical accommodations under state laws or the Americans with Disabilities Act (ADA). These are unprecedented developments for an industry that previously operated entirely outside federal legal protection.
Setting the Stage for the Upcoming June Administrative Hearings
Much of the immediate uncertainty surrounding this historic policy shift converges on the highly anticipated administrative hearing scheduled to begin on June 29, 2026. While initial public discussions occasionally point to the very end of June or June 28th, the official Federal Register notice confirms that the formal proceedings will officially kick off on the morning of June 29th at the Drug Enforcement Administration hearing facility in Arlington, Virginia.
This expedited hearing, mandated to wrap up no later than July 15, 2026, is specifically designed to address the glaring regulatory questions left unanswered by the initial medical-only reclassification order. Chief among these is whether marijuana as a whole, including the massive adult-use and recreational sectors that currently dominate states like Ohio, will be uniformly moved to Schedule III.
Hearings to Present Evidence of Medical Efficacy of Cannabis
Legal analysts at Morgan Lewis emphasize that the extraordinarily compressed timeline for this hearing reflects a calculated push by the federal administration to bypass the administrative gridlock that stalled previous cannabis reform efforts. The Department of Justice is signaling its intent to finalize a comprehensive rule as quickly as possible.The hearing runs June 29 through July 15, 2026, at the DEA Hearing Facility, 700 Army Navy Drive, Arlington, Virginia 22202, with a recess July 3–6 for Independence Day.
If successful, this process could lead to a final federal order being published by late summer, which would help resolve the confusing dual-tier system that currently forces businesses to separate medical and recreational operations for tax and compliance purposes.
The June hearings will serve as the primary legal battleground for receiving expert testimonies and factual evidence regarding the abuse potential and medical efficacy of the entire cannabis plant supply chain. This means the presiding administrative law judge will look beyond finished, state-licensed medical products to evaluate the scheduling of bulk cannabis, raw extracts, and cultivation practices.
What Does Rescheduling Means for Ohioans?
The outcomes of these midsummer sessions will ultimately dictate whether the entire state-regulated market can fully shed its federal Schedule I status, or if recreational commerce will continue to operate under a separate, more legally volatile reality while the medical sector moves ahead.
For residents of Ohio, this federal shift lands in the middle of an already rapidly evolving state market. Ohio has a dual-tier framework where both medical patients and adult-use consumers access the market side by side. The federal rescheduling order directly splits these two groups of Ohioans, reshaping how patients navigate their care and how consumers interact with the commercial market.
Ohioans holding a valid medical marijuana card stand to benefit almost immediately from increased workplace protections, as Ohio employers will find it increasingly difficult to justify zero-tolerance terminations for off-duty medical use now that the federal government officially recognizes its therapeutic value.
Complex Accounting and Operational Puzzle
Ohio dispensaries that service both medical patients and recreational consumers are facing a complex accounting and operational puzzle. Because the Schedule III tax benefits apply strictly to the medical side of the business, dual-licensed dispensaries in Ohio would need to meticulously separate their medical revenues and expenses from their adult-use sales to comply with the IRS. This operational hurdle could incentivize some Ohio dispensaries to prioritize their medical patient base, potentially leading to better pricing, loyalty programs, or specialized product availability for registered patients.
The Drug Enforcement and Policy Center at the Ohio State University Moritz College of Law highlighted that the reclassification will significantly lower the bureaucratic barriers for scientific research. For Ohio patients suffering from qualifying conditions like chronic pain, PTSD, or epilepsy, this means colleges like Ohio State, the Cleveland Clinic, and Case Western Reserve University can study the long-term efficacy of cannabis with far less federal red tape.
Key Deadline: May 24th Email
While federal regulators and judicial figures are currently setting the explicit parameters of this drug policy overhaul, everyday citizens hold substantial power in determining what the final landscape looks like. The ongoing administrative process offers formal mechanisms for public engagement that should not be ignored. According to official guidelines published in the Federal Register, the Drug Enforcement Administration accepts formal electronic comments and requests to participate in the upcoming rulemaking process. With key deadlines fast approaching—including the May 24th cutoff for submitting electronic documentation via email directly to the agency administration—the window for the public to directly influence federal cannabis policy is open right now.
Ohio cannabis consumers, medical patients, and industry stakeholders have a unique opportunity to shape how these laws reconcile the current split between medical and adult-use systems. By actively participating in these official comment windows and reaching out directly to congressional representatives, voters can voice their concerns regarding workplace discrimination, fair market access, and the necessity of uniform federal rules. Taking regular action ensures that the federal government hears directly from the individuals whose healthcare, livelihoods, and personal freedoms are impacted by these changes.
How to Comment
If you are an “interested person”—such as a consumer, medical patient, legal expert, or business owner whose livelihood or healthcare is directly affected—you can formally apply to participate in the upcoming hearings. It is important to note that any participation requests submitted during the 2024 or 2025 comment periods do not carry over; a brand-new notice must be filed.
- Electronic Submission: Each notice must: (1) state with particularity the person’s interest in the proceeding; (2) identify the specific objections or issues to be addressed; and (3) briefly state the person’s position. Submit electronic notices as a PDF to nprm@dea.gov (referencing “Docket No. DEA-1362”) by 11:59 p.m. ET on May 24, 2026.
- Mail-In Submission: If you prefer physical mail, your written notice must be postmarked on or before May 20, 2026, and sent to the following address:
Drug Enforcement Administration
Attn: Administrator
8701 Morrissette Drive
Springfield, VA 22152
To stay up to date on the latest cannabis news, patient and consumer rights in Ohio:
Subscribe to our Newsletter: Join the MedicateOH & MedicateKY Community
Join our Social Channels: Connect with us on social media to be part of the discussion: Facebook |Instagram |LinkedIn |Reddit
